Quick Answer
ACRO BIOMEDICAL CO., LTD. reported R&D Expense of $0.00 for fiscal year 2024.
ACRO BIOMEDICAL CO., LTD. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $0.00 | -100.0% |
| 2023 | $4.79M | -52.4% |
| 2022 | $10.08M | +90.7% |
| 2021 | $5.29M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | $0.00 | -100.0% | — |
| June 30, 2024 | $0.00 | -100.0% | — |
| March 31, 2024 | $0.00 | -100.0% | -100.0% |
| September 30, 2023 | $396.6K | -84.3% | -78.9% |
| June 30, 2023 | $1.88M | -25.5% | -25.5% |
| March 31, 2023 | $2.52M | +0.0% | +0.0% |
| September 30, 2022 | $2.52M | +18.7% | +0.0% |
| June 30, 2022 | $2.52M | +292.7% | +0.0% |
- ACRO BIOMEDICAL CO., LTD. showed a decrease of -100.0% in R&D Expense compared to the prior fiscal year.
- Over the 2021–2024 period, ACRO BIOMEDICAL CO., LTD.’s r&d expense has declined by 100.0% (from $5.29 million to $0.00).
- The most recent figure is from ACRO BIOMEDICAL CO., LTD.’s fiscal year 2024 report (Form 10-K), filed with the SEC on July 24, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: